Markston International’s Teva Pharmaceuticals TEVA Stock Holding History

Markston International’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-27,249	Closed	-$905K	–	186
2017 Q2	$905K	Hold	27,249	–	–	0.09%	103
2017 Q1	$874K	Hold	27,249	–	–	0.09%	106
2016 Q4	$988K	Hold	27,249	–	–	0.09%	109
2016 Q3	$1.25M	Hold	27,249	–	–	0.12%	105
2016 Q2	$1.37M	Hold	27,249	–	–	0.13%	108
2016 Q1	$1.46M	Sell	27,249 -2,000	-7%	-$117K	0.14%	107
2015 Q4	$1.92M	Sell	29,249 -4,700	-14%	-$290K	0.16%	109
2015 Q3	$1.92M	Sell	33,949 -13,101	-28%	-$849K	0.17%	109
2015 Q2	$2.78M	Hold	47,050	–	–	0.2%	112
2015 Q1	$2.93M	Sell	47,050 -24,500	-34%	-$1.42M	0.2%	113
2014 Q4	$4.12M	Sell	71,550 -1,900	-3%	-$106K	0.26%	105
2014 Q3	$3.95M	Sell	73,450 -2,500	-3%	-$132K	0.24%	105
2014 Q2	$3.98M	Hold	75,950	–	–	0.24%	109
2014 Q1	$4.01M	Hold	75,950	–	–	0.25%	108
2013 Q4	$3.04M	Sell	75,950 -1,000	-1%	-$39.4K	0.19%	114
2013 Q3	$2.91M	Sell	76,950 -1,500	-2%	-$58.5K	0.2%	113
2013 Q2	$3.08M	Buy	+78,450	New	+$3.06M	0.2%	113

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Markston International's TEVA Position: Q3 2017 in Review

Markston International sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 27,249 shares — an estimated $905K sold.

Markston International first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $4.12M in Q4 2014. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Markston International reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Markston International sold 27,249 Teva Pharmaceuticals shares in Q3 2017, an estimated $905K.
Markston International first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Markston International's Teva Pharmaceuticals position peaked at $4.12M in Q4 2014.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Markston International's 13F filing for Q3 2017, filed 7 Nov 2017.